We are live on ! Find out more
SRRA

Sierra Oncology, Inc. Common Stock
SRRA

Delisted

SRRA was delisted on the 30th of June, 2022.

Back to rankings

59 hedge funds and large institutions have $81.2M invested in Sierra Oncology, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

27% more capital invested

Capital invested by funds: $64M → $81.2M (+$17.2M)

3% less funds holding

Funds holding: 61 → 59 (-2)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

50% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 18

Holders
59
Holders Change
-2
Holders Change %
-3.28%
% of All Funds
1.28%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.06%
New
7
Increased
9
Reduced
18
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
+$366K
2
6CM
683 Capital Management
New York
+$224K
3
TI
Telemetry Investments
New York
+$188K
4
Renaissance Technologies
Renaissance Technologies
New York
+$139K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$127K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$792K
2
AG
Algert Global
California
-$431K
3
SFM
Sphera Funds Management
Israel
-$341K
4
O
OrbiMed
New York
-$160K
5
PM
Prosight Management
Texas
-$154K
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
26
Boothbay Fund Management
New York
$208K – – –
TI
27
Telemetry Investments
New York
$200K +$188K +2,928 New
AG
28
Algert Global
California
$138K -$431K -6,711 -77%
CI
29
Cowen Inc
New York
$128K +$40.1K +625 +50%
FAM
30
Fred Alger Management
New York
$127K – – –
Two Sigma Investments
31
Two Sigma Investments
New York
$81K -$14.9K -232 -16%
WS
32
Wedbush Securities
California
$75K – – –
Connor, Clark & Lunn Investment Management (CC&L)
33
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$70K -$12.8K -200 -16%
Millennium Management
34
Millennium Management
New York
$67K -$26K -405 -29%
ASN
35
Advisory Services Network
Georgia
$64K – – –
RJT
36
Raymond James Trust
Florida
$62K – – –
Two Sigma Advisers
37
Two Sigma Advisers
New York
$61K +$19.9K +310 +53%
Geode Capital Management
38
Geode Capital Management
Massachusetts
$60K – – –
William Blair & Company
39
William Blair & Company
Illinois
$50K +$19.9K +310 +73%
PAM
40
Panagora Asset Management
Massachusetts
$49K +$5.01K +78 +12%
Bank of America
41
Bank of America
North Carolina
$45K +$42.5K +662 New
OAM
42
Oxford Asset Management
United Kingdom
$43K -$64.3K -1,002 -62%
Comerica Bank
43
Comerica Bank
Texas
$37K – – –
Russell Investments Group
44
Russell Investments Group
United Kingdom
$34K +$2.76K +43 +9%
COI
45
Connable Office Inc
Michigan
$33K – – –
VF
46
Virtu Financial
New York
$32K +$29.9K +466 New
D.E. Shaw & Co
47
D.E. Shaw & Co
New York
$30K -$2.57K -40 -8%
RC
48
RBF Capital
California
$28K – – –
BCM
49
Brookstone Capital Management
Illinois
$28K +$26.4K +411 New
Wells Fargo
50
Wells Fargo
California
$27K – – –
1
2
3

SRRA Hedge Fund Activity: Q1 2019 in Review

59 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q1 2019, worth a combined $81.2M — up 27% from $64M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of SRRA and 7 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 9 added.

The largest buyer was Bridgeway Capital Management, adding an estimated $366K. The largest seller was Citadel Advisors, cutting an estimated $792K.

  • 59 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q1 2019, down from 61 in Q4 2018.
  • Funds reported $81.2M of Sierra Oncology, Inc. Common Stock stock for Q1 2019, up 27% quarter-over-quarter.
  • 7 funds opened new Sierra Oncology, Inc. Common Stock positions in Q1 2019 and 9 closed out, a net change of -2 holders.
  • The largest Sierra Oncology, Inc. Common Stock buyer in Q1 2019 was Bridgeway Capital Management, an estimated $366K added.
  • The largest Sierra Oncology, Inc. Common Stock seller in Q1 2019 was Citadel Advisors, an estimated $792K sold.

Based on aggregated 13F filings for Q1 2019.